Skip to content

Maze Therapeutics

US · MAZE #2998 by market cap Listed 2025
31.37 -1.06 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.
    SEC · 2025/9/25
  • Rating change
    Wedbush Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/9/23
  • Company notice
    Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.
    SEC · 2026/1/9
  • H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/11/11
  • Rating change
    J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating
    Market Newswire · 2026/10/27
  • J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $51
    Market Newswire · 2026/11/11
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)
    TipRanks · 2026/9/23
  • Company notice
    Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.
    SEC · 2025/11/6
  • Company notice
    Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.
    SEC · 2025/2/4
  • Rating change
    CCORF Initiates Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/10/19
  • Rating change
    Citi Initiates Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/9/24
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)
    TipRanks · 2026/9/23
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)
    TipRanks · 2026/10/21
  • Rating change
    A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110
    Market Newswire · 2026/9/23
  • Rating change
    Maze Therapeutics, Inc. (MAZE) Gets a Buy From Wells Fargo
    TipRanks · 2026/10/15
  • Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/11/11
  • Company notice
    GiXo: Gix Makes Maze Co., Ltd. a Subsidiary - Strengthening the System to Promote the Data Infrastructure Utilization Service “CU/ADS (Quads)”
    JPX · 2025/10/2
  • Rating change
    HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
    Benzinga · 2026/9/24
  • Citi Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/11/10
  • BTIG Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/11/10
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
    TipRanks · 2026/9/10
  • Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/10/15
  • H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/10/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)
    TipRanks · 2026/9/23
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
    TipRanks · 2026/9/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Maze Therapeutics discussion 0 comments

Add a comment